An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athersys to Participate in International Stroke Conference and BioProcess International
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Athersys, Inc. (NASDAQ: ATHX) announced its participation in two significant conferences: the International Stroke Conference 2023, taking place from February 8-10 in Houston, TX, and BioProcess International US West from February 27 to March 2 in San Diego, CA. Athersys invites registered attendees to schedule meetings with Ellen Gurley at ir@athersys.com. At the BioProcess International event, Vice President Senthil Ranganathan will present on March 1, discussing the commercialization pathway of MultiStem®, Athersys's allogeneic stem cell therapy. For more information, visit the respective conference websites.
Positive
None.
Negative
None.
CLEVELAND--(BUSINESS WIRE)--
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA. Any registered attendees interested in meeting with Athersys at either conference can contact Ellen Gurley at ir@athersys.com to set up a meeting.
Hosted by the American Heart Association, ISC is the world’s premier meeting for clinicians and scientists dedicated to advancing research and treatment of cerebrovascular disease and brain health. Attending the conference provides the opportunity to collaborate with thousands of colleagues in the stroke field from around the world. Please visit https://professional.heart.org/en/meetings/international-stroke-conference for additional information and registration.
Additionally, Senthil Ranganathan, Vice President of Technical Operations, will be attending and speaking at the BioProcess International US West conference in San Diego. On March 1, Senthil will be giving a talk titled, “The Path to Commercialization of an Allogeneic Stem Cell Therapy: a MultiStem® Perspective.” Details on his session are below. Please visit https://informaconnect.com/bpi-west/ for additional information and registration.
Event:
The Path to Commercialization of an Allogeneic Stem Cell Therapy: a MultiStem® Perspective
Date:
Wednesday, March 1, 2023
Time:
11:00 AM Pacific Time
Location:
San Diego Convention Center, 111 W Harbor Dr, San Diego, CA 92101
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Athersys Ellen Gurley Manager of Corporate Communications and Investor Relations
ir@athersys.com
LHA Investor Relations
Tirth T. Patel 212-201-6614
tpatel@lhai.com
Source: Athersys, Inc.
FAQ
What conferences will Athersys (ATHX) participate in February 2023?
Athersys will participate in the International Stroke Conference 2023 in Houston, TX, from February 8-10 and BioProcess International US West in San Diego, CA, from February 27 to March 2.
Who will represent Athersys at the BioProcess International US West conference?
Vice President Senthil Ranganathan will represent Athersys and is scheduled to speak on March 1, 2023.
What is the topic of Senthil Ranganathan's talk at the BioProcess International conference?
His talk is titled 'The Path to Commercialization of an Allogeneic Stem Cell Therapy: a MultiStem Perspective.'
How can I contact Athersys for meetings at the conferences?
Interested parties can contact Ellen Gurley via email at ir@athersys.com to set up meetings.
What is MultiStem<sup>®</sup> developed by Athersys (ATHX)?
MultiStem® is an allogeneic stem cell therapy currently in clinical development for critical care indications.
